Fusion protein for targeted degradation of cell endogenous protein and application
By constructing a fusion protein between the RING domain of the Trim21 protein and the target protein, and using protein delivery media to achieve intracellular ubiquitination degradation, the problems of low targeted degradation efficiency and selectivity limitation in the prior art are solved, and the "unfair" situation is achieved Highly efficient degradation and target expansion of patent medicines.
Patent Information
- Application Number
- CN202411188218.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-29
AI Technical Summary
The existing targeted protein degradation strategies have limited regulatory effects on "unprepared" proteins, and the TRIM21 protein has a large molecular structure, the E3 ubiquitin ligase activity is regulated by its own B-Box domain, and the RING domain is prone to its own ubiquitination. This leads to low degradation efficiency and target selectivity limitation.
A fusion protein was constructed, and the RING domain of the E3 ubiquitinated ligase activity of Trim21 protein is fused with the binding molecule of the target protein through a linking peptide, and it is delivered to the cell using a protein delivery medium to form a ubiquitinated complex. To achieve the degradation of the target protein, the "Trim-away" strategy is simplified and the active center of the RING domain is retained.
It has achieved efficient degradation of "unprepared" targets, expanded the target range, solved the problem of selectivity limit of drug targets and off-targeting of chemical small molecule drugs in the PROTACs method, and the degradation rate of target proteins reaches 50-60%, and Distinguish different mutants.
Smart Images

Figure HDA0005014177540000011 
Figure HDA0005014177540000012 
Figure HDA0005014177540000013
Abstract
Description
(I) Technical field
[0001] The invention relates to a fusion protein for targeted degradation of endogenous cell proteins and application thereof. (II) Background technology
[0002] Proteins participate in many physiological processes in cells and are the main bearers of life activities. Once protein homeostasis is destroyed, diseases will occur, so maintaining protein homeostasis in cells is of great significance. For a long time, regulating protein homeostasis in cells has been the goal of biological and medical research, and great progress has been made. However, not every protein can bind to specific small molecules and regulate its activity. These proteins that are difficult to find small molecule regulators are often considered "undruggable" proteins. How to achieve quality control of "undruggable" proteins remains an urgent problem to be solved.
[0003] Small molecule degraders (PROTACs) face the complexity of the drug screening process. The construction of controllable PROTACs must be modified by chemical groups, which leads to an increase in molecular weight and potential drug toxicity issues. Not all target proteins can be regulated by small molecules.
[0004] In 2017, Clift et al. developed a targeted protein degradation strategy called “Trim-away” ( Figure 1 ), which can rapidly degrade mammalian endogenous proteins through the UPS (Ubiquitin-proteasome system) (Cell, 2017, 171(7), 1692-1706). Trim21 protein and antibodies are the two core components of this strategy. Trim21 protein is an E3 ubiquitin ligase, and its PRSPRY domain has a high affinity with the Fc domain of antibodies. "Trim-away" delivers antibodies bound to target proteins into cells by microinjection or electroporation; then Trim21-antibody-target protein combines to form a complex, causing the target protein to be ubiquitinated and degraded by Trim21.
[0005] However, the TRIM21 protein has defects such as large molecular structure, E3 ubiquitin ligase activity is regulated by its own B-Box domain, and the RING domain is easily self-ubiquitinated. Therefore, improving the existing "Trim-away" targeted protein degradation strategy will not only simplify the entire strategy, but also maintain or even improve the degradation efficiency of endogenous proteins in mammalian cells and expand the degradation targets. This is an urgent direction for this technology to be improved. (III) Summary of the invention
[0006] The present invention aims to provide a fusion protein and application for targeted degradation of endogenous proteins in cells, wherein the RING domain of the Trim21 protein having the characteristics of an E3 ubiquitin ligase is fused with a binding molecule of a target protein in the cell through a connecting peptide to obtain a fusion protein, and the fusion protein is delivered to the cell by a protein delivery method to degrade the target protein; the fusion protein constructed by the present invention simplifies the composition of "Trim-away" ( Figure 1 ), is a new modular and specific way to degrade target proteins, and also provides new ideas for the inhibition of traditional "undruggable" targets.
[0007] The technical solution adopted by the present invention is:
[0008] The present invention provides a fusion protein for targeted degradation of endogenous proteins in cells. The fusion protein is obtained by fusing a RING domain with E3 ubiquitin ligase activity at the N-terminus of a Trim21 protein with a binding molecule of an intracellular target protein via a connecting peptide; the binding molecule comprises an affibody, a nanobody or a pseudo-antibody capable of binding to the target protein.
[0009] Furthermore, the amino acid sequence of the RING domain is shown in amino acids 8-94 in SEQ ID NO.1, and the sequence feature is that the eight amino acids in the active center are conserved, and the amino acids in these eight sites are mainly composed of cysteine (Cys) and histidine (His).
[0010] Further, the connecting peptide includes GGGGS or GGGGSGGGGS.
[0011] Furthermore, the target proteins include green fluorescent protein (GFP), α-synuclein, and Kirsten rat sarcoma viral oncogene homolog (Kras).
[0012] Furthermore, the cells include human cervical cancer cells HeLa, human cervical cancer cells labeled with green fluorescent protein (HeLa-GFP), and human epidermal cancer cells A431.
[0013] Furthermore, the amino acid sequence of the fusion protein is one of the following: SEQ ID NO.1 (denoted as RING-Af Syn , molecular weight of 17 kDa, targeting α-synuclein), SEQ ID NO.3 (denoted as RING-Nb GFP , molecular weight 23kDa, targeting green fluorescent protein), SEQ ID NO.5 (denoted as RING-Mo Ras , with a molecular weight of 21.3 kDa, targeting the Kirsten rat sarcoma viral oncogene homolog).
[0014] The present invention also provides a method for preparing the fusion protein, which comprises the following steps:
[0015] (1) The DNA sequence of the fusion protein was constructed on the pET-22b(+) vector and transformed into the competent cells of Escherichia coli BL21(DE3) by chemical transformation. A single clone was selected and inoculated into LB liquid culture medium and cultured at 37°C until the logarithmic growth phase (OD 600 =0.6-0.8), add the inducer IPTG at a final concentration of 0.5 mM and ZnCl at a final concentration of 10 μM 2 , after culturing overnight at 18°C and 180 rpm, the wet cells were collected;
[0016] (2) In step (1), the wet cells are fully suspended in a lysis buffer; the cell resuspension is ultrasonically disrupted for 35 min at 25 W in an ice bath, with a working time of 2 s and an interval of 3 s. After the ultrasonication, the cell is centrifuged at 4° C. and 8000 rpm for 10 min, and the supernatant is collected to obtain a crude protein enzyme solution; the lysis buffer is a pH 8.0, 50 mM Tris-HCl buffer containing 10 mM imidazole, 300 mM sodium chloride, 1 mM dithiothreitol (DTT), and 0.1 mM phenylmethylsulfonyl chloride (PMSF); the volume ratio of the lysis buffer to the wet cells is 1:5-15 (preferably 1:10);
[0017] (3) The crude protein enzyme solution of step (2) is loaded onto a Ni-NTA column with a loading volume of 10 column volumes, and the column is drained by gravity. The target protein is eluted by gravity with eluents containing 20 mM, 40 mM, 60 mM, 100 mM, and 300 mM imidazole in turn, with each concentration eluting for 10 column volumes. The effluent corresponding to the eluents of 60 mM, 100 mM, and 300 mM imidazole is collected to obtain a pure protein solution, which is the fusion protein; the eluent is a pH 8.0, 20 mM Tris-HCl buffer containing 300 mM sodium chloride; the crude protein enzyme solution is first mixed with Ni-NTA Agarose (QIAGEN, the added volume of Ni-NTA Agarose is calculated based on the protein load of Ni-NTA Agarose being 50 mg / mL) before loading; and then the column is placed at 4° C. and rotated slowly to allow the Ni-NTA Agarose was fully bound to the target protein and taken out after 1 hour as the loading solution; the Ni-NTA column was washed with 1×PBS (1.06 mM KHPO 4 , 154 mM NaCl, 5.6 mM NaHPO 4 , pH 7.4) by gravity elution twice, remove the ethanol solution and wash with ddH 2 O and then add the loading solution.
[0018] The present invention also provides an application of the fusion protein in targeted degradation of endogenous target proteins in cells, and the application method is: the fusion protein is delivered to cells by means of a protein delivery medium, the fusion protein binds to the endogenous target protein in the cells to form a ternary complex (Target / Target binder / RING), and finally the RING in the fusion protein plays the role of E3 ubiquitin ligase to achieve degradation of the endogenous target protein in the cells through the ubiquitin proteasome system; the protein delivery medium includes a metal organic framework MOF, an endolytic peptide L17E, and a transmembrane polypeptide A5K.
[0019] Furthermore, the amino acid sequence of the endolytic peptide L17E is shown in SEQ ID NO. 14 (IWLTALKFLGKHAAKHEAKQQLSKL), with a molecular weight of 2.86 kDa, and was developed by Shiroh Futaki's research group (Nature Chemistry, 2017, 9, 751-761). The delivered protein can effectively escape from the lysosomal vesicles with the assistance of the endolytic peptide (L17E), thereby promoting the cell's uptake of the delivered protein.
[0020] Furthermore, the amino acid sequence of the transmembrane polypeptide A5K is SEQ ID NO.13 (GLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR), with a molecular weight of 4 kDa, reported by Ross C. Wison et al. (Nature Biomedical Engineering, 2023, 7, 647-660). The polypeptide can mediate protein entry into cells. These two polypeptides have the advantages of high biocompatibility, simple operation, and low toxicity and side effects.
[0021] Furthermore, the method for delivering the fusion protein using a metal organic framework MOF is as follows: (1) adding a pure protein solution of the fusion protein to an aqueous solution containing 2-methylimidazole under vigorous stirring at 30°C and 1000 rpm, incubating for 5 minutes, then slowly dropping an aqueous solution of zinc nitrate hexahydrate, stirring at 30°C and 1000 rpm for 10 minutes, centrifuging at 12000 rpm for 10 minutes, washing the precipitate with deionized water three times to remove the residue, and drying at 40°C overnight to obtain a nano-metal organic framework loaded with the fusion protein; the protein concentration of the fusion protein aqueous solution is The concentration of the aqueous solution of zinc nitrate hexahydrate is 0.45 M, the feed ratio of the fusion protein to 2-methylimidazole is 0.25 mg / 3.15 mmol, and the feed ratio of the fusion protein to zinc nitrate hexahydrate is 0.25 mg / 0.045 mmol; (2) diluting the nanometal organic framework loaded with the fusion protein in step (1) with deionized water, slowly adding cetuximab Cet solution (the solvent is PBS, which has tumor cell targeting and binds to the cell surface EGFR receptor, ACS Chemistry Biology, 2021, 17(1), 32-38), incubating at 4°C for 2 hours with continuous stirring to obtain a nanomaterial solution with antibody protein attached to the surface; (3) incubating the nanomaterial solution with antibody protein attached to the surface in step (2) with cells to deliver the fusion protein into the cells.
[0022] Furthermore, the method for delivering the fusion protein using the endosoluble peptide L17E and the transmembrane polypeptide A5K is as follows: the fusion protein is incubated with the endosoluble peptide L17E or the transmembrane polypeptide A5K at 25° C. for 30 minutes, and then incubated with cells, thereby delivering the fusion protein into the cells.
[0023] The present invention first fuses the RING domain with a binding molecule (Target binder) of an intracellular target protein (such as an affibody, a nanobody, or a monobody) through a connecting peptide to obtain a fusion protein; secondly, the fusion protein is delivered to the cell with the aid of a protein delivery medium (including metal organic frameworks MOFs, intracellular soluble peptide L17E, and cell transmembrane polypeptide A5K). The fusion protein then binds to the target protein to form a ternary complex (Target / Target binder / RING); finally, the RING domain usually coordinates two Zn 2+The ions recognize the E2 coupling enzyme in a cross-support manner, and the ubiquitin bound to E2 is connected to the target protein through the action of the RING domain E3 ubiquitination ligase to form a ubiquitinated target protein. The ubiquitinated target protein is recognized by the proteasome and broken down into short peptides or amino acids, thereby degrading the target protein.
[0024] Compared with the prior art, the beneficial effects of the present invention are mainly reflected in:
[0025] The present invention aims at the defects of TRIM21 protein, such as large molecular structure, E3 ubiquitin ligase activity regulated by its own B-Box domain, and RING domain being easily self-ubiquitinated, to simplify the existing "Trim-away" targeted degradation strategy, remove the unnecessary domains of Trim21 protein, retain its active center, select the RING domain of Trim21 protein and fuse it with the binding molecule of the target protein in the cell to obtain a fusion protein. The protein components of the fusion protein provided by the present invention are uniform, multi-step chemical synthesis is not required, and it can be expressed in large quantities and stably in Escherichia coli.
[0026] The fusion protein of the present invention can be modularly customized according to the target protein to be degraded, which not only expands the degradation range of the target protein in the cell, but also acts on "undruggable" proteins, thereby enriching the target library and solving the problems of selectivity limitation of drug targets and off-target of chemical small molecule drugs in the PROTACs method. At the same time, the fusion protein of the present invention can also distinguish different mutants of the target protein.
[0027] The fusion protein of the present invention can be delivered into cells through protein delivery media (including metal organic frameworks MOFs, intracellular soluble peptide L17E, and cell transmembrane polypeptide A5K) to exert its effect, thereby effectively degrading the target protein, and the degradation rate of the target protein reaches 50-60%.
[0028] The present invention represents a general strategy for synthetic convenience and selective targeted protein degradation, thereby expanding the potential applications of current fusion protein-related technologies in drug development. (IV) Description of the drawings
[0029] Figure 1 Schematic diagram of the fusion protein degrading endogenous cellular proteins.
[0030] Figure 2 RING-Af predicted by AlphaFold2 Syn (A) RING-Nb GFP (B) RING-Mo Ras (C) Protein folding structure.
[0031] Figure 3 RING-Af Syn(A) RING-Nb GFP (B) RING-Mo Ras (C) Schematic diagram of structural composition.
[0032] Figure 4 This is the SDS-PAGE image of the fusion protein extraction and purification process stained with Coomassie Brilliant Blue; A represents RING-Af Syn , B stands for RING-Nb GFP , C stands for RING-Mo Ras ; P represents the precipitate after ultrasonic cell disruption; S represents the supernatant after ultrasonic cell disruption; FT represents the flow-through; W1 represents the effluent containing 20 mM imidazole eluent, W2 represents the effluent containing 40 mM imidazole eluent; E1 represents the effluent containing 60 mM imidazole eluent, and E2 represents the effluent containing 100 mM imidazole eluent.
[0033] Figure 5 Western blot analysis of the in vitro self-ubiquitination ability of RING; A represents blank control, RING, and RING-Af Syn 、RING-Nb GFP Western blot of the monoubiquitination degree of fusion proteins; B represents blank control, RING, RING-Af Syn 、RING-Nb GFP Western blot of the polyubiquitination degree of fusion proteins; C represents blank control, RING, RING-Mo Ras Western blot of monoubiquitination degree of fusion proteins; D represents blank control, RING, RING-Mo Ras Western blot of the polyubiquitination degree of the fusion proteins.
[0034] Figure 6 RING-Nb GFP Western blot of GFP ubiquitination (A) and RING-Nb GFP Native Page protein fluorescence gel image detecting its binding ability with GFP (B).
[0035] Figure 7 This is the transmission electron microscopy (TEM) image of GFP@MOF@Cet nanomaterials.
[0036] Figure 8 GFP@MOF@Cet, GFP@MOF and RING-Nb GFP GFP protein blot image of human cervical cancer cells (HeLa-GFP) stably expressing green fluorescent protein after being treated with @MOF@Cet.
[0037] Fig. 9 RING-GFPNb Western blotting of GFP after co-incubation with different concentrations of A5K to treat human cervical cancer cells stably transfected with green fluorescent protein (HeLa-GFP).
[0038] Fig.10 For RING-Mo Ras Western blot of Kras after @MOF@Cet treated human cervical cancer cells HeLa.
[0039] Fig.11 The intracellular soluble peptide L17E and RING-Af Syn Western blot of α-Synuclein in human cervical cancer cells HeLa after co-incubation. (V) Specific implementation methods
[0040] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto:
[0041] The methods are conventional methods unless otherwise specified. The raw materials can be obtained from public commercial channels unless otherwise specified.
[0042] Cell culture medium: DMEM complete medium containing 10% fetal bovine serum (FBS) + penicillin (100 μg / mL) + streptomycin (100 μg / mL).
[0043] Example 1: Fusion protein RING-Af Syn 、RING-Nb GFP 、RING-Mo Ras Construction and expression purification of
[0044] 1. Construction of fusion protein
[0045] according to Figure 1 Principle, reference Figure 3 The N-terminus of the RING domain at the N-terminus of the Trim21 protein was connected to a His tag (MHHHHHH), and the C-terminus was connected to the binding molecules of the target protein: green fluorescent protein (GFP), α-synuclein (α-Synuclein), and Kirsten rat sarcoma viral oncogene homolog (Kras) through a connecting peptide (GGGGS or GGGGSGGGGS) to construct a fusion protein. The protein folding structure predicted by AlphaFold2 is shown in Figure 2 .
[0046] Fusion protein RING-Af with His tag (MHHHHHH) Syn 、RING-Nb GFP 、RING-Mo RasThe DNA sequence was completed by Nanjing GenScript. Syn The amino acid sequence of the gene is shown in SEQ ID NO.1, and the nucleotide sequence of the gene is shown in SEQ ID NO.2; the fusion protein RING-Nb with a His tag GFP The amino acid sequence of the gene is shown in SEQ ID NO.3, and the nucleotide sequence of the gene is shown in SEQ ID NO.4; the fusion protein RING-Mo with a His tag Ras The amino acid sequence of is shown in SEQ ID NO.5, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.6. Meanwhile, Nanjing GenScript Company synthesized a His-tagged protein RING (RING amino acid sequence is shown in SEQ ID NO.3, 8-94), and a His-tagged Nb GFP (Nb GFP The amino acid sequence is shown in positions 100-157 of SEQ ID NO.3), and GFP with a His tag (the amino acid sequence of GFP is shown in SEQ ID NO.15).
[0047] Fusion protein RING-Af Syn The amino acid sequence of SEQ ID NO.1 (the underline represents RING, the bold part represents the connecting peptide, and the italic part represents Af Syn )
[0048] MHHHHHH GSMASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRF LLKNLRPNRQLANMVNNLKEISQEARE GGGGSVDNKFNKEMASADGEIFYLPNLNPD QLCAFFHSVHDDPSQSANLLAEAKKLNDAQAPK.
[0049] Fusion protein RING-Nb GFP The amino acid sequence of SEQ ID NO.3 (the underline represents RING, the bold part represents the connecting peptide, and the italic part represents Nb GFP )
[0050] MHHHHHH GSMASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFL LKNLRPNRQLANMVNNLKEISQEARE GGGGSMQVQLVESGGALVQPGGSLRLSCAASGFPVNRYSWYRQAPGKEREWVAGMSSAGDRSSYEDSVKGRFTISRDDARNTVYLQMNSLKPEDTAVYYCNVNVGFEYWGQGTQVTVSSK.
[0051] Fusion protein RING-Mo RasThe amino acid sequence of SEQ ID NO.5 (the underline represents RING, the bold part represents the connecting peptide, and the italic part represents Mo Ras )
[0052] MHHHHHH GSMASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFL LKNLRPNRQLANMVNNLKEISQEARE GGGGSGGGGSVSSVPTKLEVVAATPTSLLISWDAPAVTVDYYVITYGETGGNSPVQKFEVPGSKSTATISGLKPGVDYTITVYAWGWHGQVYYYMGSPISINYRT.
[0053] 2. Protein Expression
[0054] (1) The fusion protein RING-Af with His tag Syn 、RING-Nb GFP 、RING-Mo Ras As well as control proteins RING, Nb GFP The DNA sequence of GFP was constructed on pET-22b(+) or pET-24b(+) vector, with NdeI as the 5' restriction site and EcoRI as the 3' restriction site, to obtain plasmids pET-22b(+)-RING-Af Syn 、pET-22b(+)-RING-Nb GFP 、pET-22b(+)-RING-Mo Ras , pET-24b(+)-RING, pET-24b(+)-Nb GFP , pET-24b(+)-GFP.
[0055] (2) The constructed plasmid was transferred into competent E. coli BL21 (DE3) cells by chemical transformation. A single colony was picked from the plate and cultured in a 25 mL liquid LB medium containing 100 μg / mL ampicillin at 37°C and 220 rpm for 9 h as seed solution. 5 mL of seed solution was inoculated into 250 mL liquid LB medium containing 100 μg / mL ampicillin and cultured at 37°C and 220 rpm for 1-2 h until OD 600 =0.6-0.8. Add IPTG at a final concentration of 0.5 mM to induce protein expression (ZnCl is added to the medium for protein expression with RING domain) 2 To a final concentration of 10 μM, which stabilizes the target protein), culture overnight at 18°C, 180 rpm.
[0056] 3. Protein purification
[0057] Step (2) After induction of expression, the culture solution was centrifuged at 8000 rpm, 10 min, 4°C, the supernatant was discarded, and the bacterial precipitate was collected. The bacterial precipitate was washed twice with 1×PBS to remove the excess culture medium. The bacterial precipitate obtained from 150 mL of culture medium was resuspended in 15 mL of lysis buffer (the lysis buffer with RING domain needs to add 10 μM ZnCl 2 , which plays a role in stabilizing the target protein). The heavy suspension of the bacterial cell was ultrasonically disrupted for 35 minutes under 25W and ice bath conditions, working for 2s / interval for 3s. After the end of the ultrasonication, it was centrifuged at 4°C and 8000rpm for 10 minutes to obtain the precipitate and supernatant, and the supernatant was recorded as the crude enzyme solution. The Bradford method was used to measure the total protein content in the supernatant, and the supernatant and precipitate were respectively separated by SDS-PAGE ( Figure 4 ) Estimate the proportion of the target protein in the total protein. The lysis buffer is a pH 8.0, 50 mM Tris-HCl buffer containing 300 mM sodium chloride, 10 mM imidazole, 1 mM DTT (dithiothreitol), and 0.1 mM PMSF (phenylmethylsulfonyl chloride).
[0058] Ni-NTA Agarose (QIAGEN, Ni-NTA protein loading is 50 mg / mL, the amount of Ni-NTA Agarose added is estimated based on the loading amount) was added to the supernatant, and incubated at 4°C for 2 h as the loading solution. The Ni-NTA column was gravity eluted twice with 1× PBS, the ethanol solution was removed, and then eluted with ddH 2 O was washed twice, and then the sample solution was added, the sample volume was 10 column volumes, gravity flow was allowed, and the flow-through liquid was collected for SDS-PAGE ( Figure 4 The target protein was eluted by gravity with eluents containing 20mM, 40mM, 60mM, 100mM, and 300mM imidazole in sequence. Each concentration was eluted with 10 column volumes. The effluent corresponding to the eluents containing 60mM, 100mM, and 300mM imidazole was collected for each protein to obtain pure protein solution RING-Af Syn 、RING-Nb GFP 、RING-Mo Ras 、RING、Nb GFP , GFP. The purified protein solution was used to measure the protein concentration by NanoDrop, and the protein purity was tested by SDS-PAGE for subsequent experiments. The eluent was a pH 8.0, 20 mM Tris-HCl buffer containing 300 mM sodium chloride.
[0059] 4. Protein dialysis and storage
[0060] Precool 1×PBS at 4℃ in advance; select a dialysis membrane with a pore size of 3.5kDa and place it in a clean beaker and add an appropriate amount of pure water. After boiling, soak for 10 minutes, repeat boiling and soaking 3 times to activate the membrane. Add pure protein solution to the membrane, seal both ends, place it in 1×PBS precooled at 4℃, dialyze at 4℃ for 2h, and dialyze three times. After the dialysis is completed, take the intercepted liquid, add 5% glycerol, and store it in a -80℃ refrigerator for a long time.
[0061] Example 2: Detection of RING's autoubiquitination ability in vitro
[0062] 1. Plasmid and protein
[0063] The plasmid pET-24b(+)-UBE1 of ubiquitin activating enzyme E1 (Ube1, amino acid sequence as shown in SEQ ID NO.7, nucleotide sequence as shown in SEQ ID NO.8) was purchased from Addgene and stored and transported in the form of E. coli DH5α strain. The genes of ubiquitin conjugating enzyme E2W (UBe2w, amino acid sequence as shown in SEQ ID NO.9, nucleotide sequence as shown in SEQ ID NO.10) and recombinant human ubiquitin conjugating enzyme (UbcH5c, amino acid sequence as shown in SEQ ID NO.11, nucleotide sequence as shown in SEQ ID NO.12) were obtained from human cDNA library, and after six His were inserted at the N-terminus, plasmids pET-24b(+)-UBE2W and pET-24b(+)-Ubch5c were synthesized by GenScript, and the plasmids were transported in the form of lyophilized powder. E. coli DH5α was used for plasmid extraction, and E. coli BL21 was used for expressing proteins UBE1, UBE2W, and Ubch5c. The expression and purification of the proteins were the same as those of the fusion protein in Example 1.
[0064] 2. In vitro autoubiquitination reaction
[0065] 1) The monoubiquitination system of the fusion protein consists of: 1 μM Ube1, 1 μM Ube2w, 20 μM Ub (ubiquitin), 2 μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 2 μM RING-Af Syn / RING-Nb GFP / RING-Mo Ras , 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) was used to make up the total system to 20 μL.
[0066] The polyubiquitination system of the fusion protein consists of: 1 μM Ube1, 1 μM UbcH5c, 20 μM Ub (ubiquitin), 2 μL 10× ATP-MgCl2 (100 mM ATP, 100 mM MgCl 2 ), 2 μM RING-Af Syn / RING-Nb GFP / RING-Mo Ras , 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) was used to make up the total system to 20 μL.
[0067] Monoubiquitination control system: 1μM Ube1, 1μM Ube2w, 20μM Ub (ubiquitin), 2μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) was used to make up the total system to 20 μL.
[0068] Polyubiquitination control system: 1μM Ube1, 1μM UbcH5c, 20μM Ub (ubiquitin), 2μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) was used to make up the total system to 20 μL.
[0069] RING monoubiquitination system: 1μM Ube1, 1μM Ube2w, 20μM Ub (ubiquitin), 2μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 2 μM RING, and 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) to make up the total system to 20 μL.
[0070] RING polyubiquitination system: 1 μM Ube1, 1 μM UbcH5c, 20 μM Ub (ubiquitin), 2 μL 10× ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 2 μM RING, and 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) to make up the total system to 20 μL.
[0071] Melt the reagents required in the above 6 systems on ice and add them to the marked EP tube. After mixing, place the EP tube in a constant temperature reaction at 37°C for 2 hours. Add 5 μL of 5×SDS-PAGE protein loading buffer, boil the sample at 95°C for 10 minutes, perform polyacrylamide gel electrophoresis, and then detect the autoubiquitination level by protein immunoblotting.
[0072] 2) Western blotting to verify the level of ubiquitination
[0073] After the transfer, the PVDF membrane was soaked in TBST buffer (10mM Tris, 150mMNaCl, 0.1% Tween-20, solvent is water, pH 7.4) containing 5% skim milk powder, and blocked by shaking at room temperature for 1.5h. Washed three times with TBST buffer, 10min each time, and then added 10mL diluted Anit-Rabbit-UB antibody (1:5000 dilution, purchased from Beyotime, diluted with TBST buffer containing 3% BSA), and incubated overnight at 4°C. Washed 3 times with TBST buffer. Then, 5mL diluted HRP-conjugated goat anti-rabbit IgG (initial concentration 0.2mg / mL, purchased from Thermo Fisher, diluted with TBST buffer containing 3% BSA, 1:7500 dilution) was added to the membrane, incubated at room temperature for 1h, and washed three times with TBST buffer. Finally, the Invitrogen iBright FL1500 imaging system was used for imaging, and the A solution and B solution in the ECL kit were mixed in equal volumes for color development and exposure, and the data were analyzed. Figure 5 As shown in A and C, at the same E3 ligase (RING) concentration and reaction time, the fusion protein can achieve monoubiquitination; Figure 5 As shown in B and D, at the same E3 ligase (RING) concentration and reaction time, the fusion protein can achieve polyubiquitination, indicating that the activity of RING will not be affected after the fusion of the binding molecule.
[0074] Example 3: Ability of RING to ubiquitinate GFP protein
[0075] 1. RING-Nb GFP Ubiquitination reaction system: 1μM Ube1, 1μM Ube2w, 20μM Ub (ubiquitin), 2μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 0.05mg / mL GFP, 450nM RING-Nb GFP , 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) was used to make up the total system to 20 μL.
[0076] Control system: 1μM Ube1, 1μM Ube2w, 20μM Ub (ubiquitin), 2μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 ), 0.05 mg / mL GFP, and 10× ubiquitination buffer (1 M Tris-HCl, 6.6 mM DTT, pH 7.4) were used to make up the total system to 20 μL.
[0077] Nb GFP Ubiquitination reaction system: 1μM Ube1, 1μM Ube2w, 20μM Ub (ubiquitin), 2μL 10×ATP-MgCl 2 (100 mM ATP, 100 mM MgCl 2 )、0.05mg / mL GFP,450nM Nb GFP , 10× ubiquitination buffer (1M Tris-HCl, 6.6mM DTT, pH 7.4) was used to make up the total system to 20 μL.
[0078] The reagents required for the GFP ubiquitination system were melted on ice and added to the marked EP tube. After mixing, the EP tube was placed in a constant temperature reaction at 37°C for 2 hours. After the reaction, 5 μL of 5×SDS-PAGE protein loading buffer was added to terminate the reaction. The samples were boiled at 95°C for 10 minutes and then subjected to polyacrylamide gel electrophoresis. The autoubiquitination level of GFP was then detected by protein immunoblotting.
[0079] 2. Western blotting to verify the ability of ubiquitination of GFP protein
[0080] After the sample has completed the electrophoresis operation, the subsequent operation steps refer to Example 2. After the transfer is completed, the PVDF membrane is blocked with blocking solution on a shaker at room temperature for 60 minutes. After the blocking is completed, the membrane is washed three times with 1×TBST, each time for 10 minutes. Add 5mL of diluted Anti-GFP antibody (diluted with TBST buffer containing 3% BSA, purchased from Biolegend, 1:5000 dilution) and incubate at room temperature for 1.5h or incubate at 4°C overnight. After the primary antibody incubation is completed, the primary antibody is recovered and the membrane is washed 3 times with 1×TBST, each time for 10min. After the completion, the secondary antibody (secondary antibody: diluted to 1 / 7500 with 1×TBST containing 3% BSA) is incubated at room temperature for 1h. After the secondary antibody incubation is completed, the membrane is washed 3 times with 1×TBST, each time for 15min. The protein blotting results were recorded using Invitrogen iBright 1500, Figure 6 As shown in Figure A, the results show that the ubiquitination level of GFP is strictly monoubiquitinated. We found that at the same reaction time, RING-Nb GFPUnder treatment, the GFP band will move up, which also proves that the RING domain in the fusion protein is active and can ubiquitinate GFP.
[0081] 3. Native Page (non-denaturing gel) detection of RING-Nb GFP Binding ability to GFP
[0082] The non-denaturing gel does not add SDS to the sample required for gel preparation and subsequent sample preparation, and does not need to be heated, and the sample is directly loaded. The voltage is set to 100V during electrophoresis. Do not set a relatively high voltage to prevent protein degradation. It is best to place the system on ice or in a 4°C refrigerator. After running the gel, fluorescent imaging is performed by Invitrogen iBright 1500. During the non-denaturing polyacrylamide gel electrophoresis, the mobility of the protein is not only related to the isoelectric point of the protein, but also to the molecular weight and molecular shape of the protein. Among them, the isoelectric point of the protein is the most important influencing factor. The corresponding electrophoresis buffer system should be selected according to the isoelectric point of the protein; during the non-denaturing polyacrylamide gel electrophoresis, it should be noted that excessive voltage causes heat and leads to protein denaturation, so it is best to place ice cubes outside the electrophoresis tank to lower the temperature; if the molecular weight of the protein is large, the electrophoresis time can be appropriately extended to allow the target protein to have sufficient mobility to separate from other proteins, and vice versa.
[0083] The reagents needed in the GFP ubiquitination system were melted on ice and added to the labeled EP tube. After mixing, the EP tube was placed at 37°C for 2 hours. Without boiling, these samples were subjected to polyacrylamide gel electrophoresis at 4°C, and the electrophoresis voltage was controlled at 100V or less. After the electrophoresis, fluorescent gel scanning was performed using Invitrogen iBright 1500. The results are shown in Figure 6 Middle B.
[0084] Since GFP itself has green fluorescence, Nb GFP No green fluorescence, when it is combined with GFP, the results are obtained by imaging the non-denaturing gel using the Invitrogen iBright FL1500 imaging system ( Figure 6 From B), we can see that Nb GFP After binding to GFP, the band moves up, indicating that the Nb in the fusion protein we expressed binds to the target protein GFP. GFP Some of them still remain active and can bind to GFP, and the RING domain does not affect Nb GFP activity.
[0085] Example 4: Delivery of fusion protein RING-Nb via metal organic framework GFP Effect on degradation of endogenous GFP in cells
[0086] 1. Preparation of materials
[0087] (1)RING-Nb GFP @MOF@Cet:
[0088] ① Under vigorous stirring at 30°C and 1000 rpm, 0.125 mL of the fusion protein RING-Nb prepared by the method of Example 1 with a protein concentration of 2 mg / mL was added. GFP The pure protein solution was added to 0.9 mL of 3.5 mol / L 2-methylimidazole aqueous solution. After 5 minutes, 0.1 mL of 0.45 mol / L zinc nitrate hexahydrate aqueous solution was slowly added. After stirring for 10 minutes, the solution was centrifuged at 12000 rpm for 10 minutes. The precipitate was washed with deionized water 3 times to remove the residue, and then dried at 40°C overnight to obtain 4 mg of nano-metal organic framework (MOF) loaded with fusion protein, with a loading rate of nearly 80% and a particle size of <200 nm. ② In order to adsorb functional antibodies on the surface of the metal organic framework, 0.2 mg of the metal organic framework loaded with fusion protein was diluted with 0.2 mL of deionized water, and 0.5 μL of 5 mg / mL antibody protein Cet solution (solvent was PBS, cetuximab Cet was purchased from Merck Co., Ltd., used to bind to the EGFR receptor on the target cell membrane) was slowly added. The solution was incubated at 4°C for 2 hours under continuous stirring to obtain a nano-material solution adsorbed with Cet, and 200 μL of 1 mg / mL RING-Nb was obtained. GFP @MOF@Cet nanomaterial solution.
[0089] (2) GFP@MOF@Cet
[0090] RING-Nb in step (1) GFP The GFP pure protein solution prepared by the method of Example 1 was replaced, and other operations were the same to obtain GFP@MOF@Cet. The transmission electron microscopy image is shown in Figure 7 , nanoparticle size <200nm.
[0091] (3) GFP@MOF
[0092] In step (1), RING-Nb GFP The GFP pure protein solution prepared by the method of Example 1 was replaced, step ② was omitted, and other operations were the same to obtain GFP@MOF.
[0093] 2. Target protein immunoblotting
[0094] Human cervical cancer cells stably expressing green fluorescent protein (HeLa-GFP) were seeded at 50,000 cells / well in a 24-well plate containing 500 μL of DMEM medium and placed at 37°C with 5% CO.2 Incubate the cells overnight to allow them to adhere to the wall. Then remove the original culture medium and add 40 μg / μL of RING-Nb GFP 500 μL of DMEM medium was added to the control group, and GFP@MOF and GFP@MOF@Cet were added at a concentration of 40 μg / μL. The blank group was added with 500 μL of DMEM medium and incubated at 37°C with 5% CO 2 After incubation in the incubator for 48 hours, the cells were washed twice with PBS, and 50 μL of RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH 7.4) containing 1 μM phenylmethylsulfonyl fluoride (PMSF) was added, and then 20 μL of 5×SDS loading buffer was added. After heating at 95°C for 10 minutes, the samples were separated by 15% SDS-PAGE and transferred to PVDF membranes. The membrane was blocked with TBST buffer containing 3% skim milk powder for 1 hour at room temperature, and 5 mL of diluted GFP antibody (diluted with TBST buffer containing 3% BSA, 1:5000 dilution) was added, incubated overnight at 4°C, and then 5 mL of diluted HRP-conjugated mouse glyceraldehyde-3-phosphate dehydrogenase antibody (initial concentration 1 mg / mL,
[0095] #HRP-60004, GENICBIO, diluted with TBST buffer containing 3% BSA, 1:8000 dilution), incubated at room temperature for 1 hour, and recorded with Invitrogen iBright 1500. The results are shown in Figure 8 As shown, the GFP protein level in the blank control group was used as a standard to compare the delivery of GFP and RING-Nb in HeLa-GFP cells by metal organic frameworks. GFP The results of immunoblotting showed that compared with the control group of GFP@MOF and GFP@MOF@Cet delivering GFP alone, RING-Nb GFP The delivery of @MOF@Cet reduced the intracellular GFP expression by nearly 28%, proving that the fusion protein of the present invention can be used for the degradation of intracellular target proteins through the metal organic framework as a delivery medium.
[0096] Example 5: Delivery of fusion protein RING-Nb via transmembrane protein A5K GFP Effect on degradation of endogenous GFP in cells
[0097] 1. Co-incubation of A5K and fusion protein
[0098] (1) 2μM A5K+1mM RING-NbGFP Incubation medium: Add 300 μL of α-MEM medium to the EP tube, add 7 μL of the fusion protein RING-Nb prepared by the method of Example 1 with an original concentration of 1 mg / mL GFP The pure protein solution (final concentration of 1 mM) was then added with 0.6 μL of transmembrane protein A5K (final concentration of 2 μM, amino acid sequence as shown in SEQ ID NO.13) with an original concentration of 1 mM, and incubated at 25°C on a mixer for 30 min.
[0099] (2) 5μM A5K+1mM RING-Nb GFP Incubation medium: 2μM A5K + 1mM RING-Nb GFP During the preparation of the incubation solution, the amount of transmembrane protein A5K was changed to 1.5 μL, making its final concentration 5 μM, and the other operations were the same.
[0100] (3) HeLa-GFP cells were seeded at 50,000 cells / well in a 24-well plate containing 500 μL of DMEM medium and incubated at 37°C with 5% CO. 2 Incubate the cells overnight in an incubator to allow them to reach 80-90% confluency. Wash twice with serum-free minimum essential medium (α-MEM medium) and divide the culture wells into 5 groups. Add 300 μL of 2 μM A5K + 1 mM RING-Nb from step (1) to group 1. GFP Incubate the solution, then add cycloheximide (CHX) at a final concentration of 10 μg / mL; Group 2 adds 300 μL of step (2) 5 μM A5K + 1 mM RING-Nb GFP Incubation medium, add cycloheximide (CHX) with a final concentration of 10 μg / mL; Group 3 adds 300 μL α-MEM medium + 1.5 μL A5K (5 μM) + cycloheximide (CHX) with a final concentration of 10 μg / mL; Group 4 adds 300 μL α-MEM medium + 7 μL fusion protein RING-Nb GFP (1 μM) cycloheximide (CHX) at a final concentration of 10 μg / mL, and group 5 was added with 300 μL α-MEM medium + cycloheximide (CHX) at a final concentration of 10 μg / mL. Incubate at 25°C for 4 hours, wash the cells twice with PBS, add 500 μL DMEM medium containing 10% FBS to each well, and incubate at 25°C for 12 hours.
[0101] 2. Target protein immunoblotting
[0102] The operation steps and process are the same as those in Example 4. The protein blot was recorded using Invitrogen iBright 1500. Fig. 9 As shown, the GFP protein level in cells treated with CHX alone was used as a standard.GFP At 2 μM CHX, the cells were mixed with different concentrations of A5K. After incubation for 12 h, the results of immunoblotting showed that the degradation rate of intracellular GFP in the group treated with fusion protein and 2 μM A5K was as high as 58% compared with that in the group treated with CHX alone. Therefore, the transmembrane protein A5K can be used for fusion protein delivery and effectively degrade intracellular target proteins.
[0103] Example 6: Delivery of fusion protein RING-Mo via metal organic framework Ras Effect on degradation of endogenous Kras in cells
[0104] 1. Preparation of materials
[0105] RING-Mo Ras The preparation methods of @MOF@Cet and GFP@MOF@Cet are the same as those in Example 4.
[0106] 2. Target Protein Immunoblotting
[0107] Human cervical cancer cells (HeLa) were seeded at 50,000 cells / well in a 24-well plate containing 500 μL of DMEM medium and placed at 37°C with 5% CO. 2 The cells were allowed to adhere to the wall overnight in the incubator. The original culture medium was then removed and the culture wells were divided into 5 groups: Group 1 was added with 500 μL DMEM culture medium; Group 2 was added with 500 μL DMEM culture medium containing 20 μg / μL GFP@MOF@Cet; Group 3 was added with 20 μg / μL RING-Mo Ras @MOF@Cet in 500 μL DMEM medium; Group 4 was supplemented with 500 μL DMEM medium containing 40 μg / μL GFP@MOF@Cet; Group 5 was supplemented with 40 μg / μL RING-Mo Ras 500 μL DMEM medium of @MOF@Cet. 37°C, 5% CO 2After incubation in the incubator for 24 hours, the cells were washed twice with PBS, and 50 μL of RIPA lysis buffer containing 1 μM phenylmethylsulfonyl fluoride was added, followed by 20 μL of 5×SDS loading buffer. After heating at 95°C for 10 minutes, the samples were separated by 15% SDS-PAGE and transferred to a PVDF membrane. The membrane was blocked with TBST buffer containing 3% skim milk powder for 1 hour at room temperature, and 5 mL of diluted Kras antibody (diluted with TBST buffer containing 3% BSA, 1:800 dilution) was added, incubated overnight at 4°C, and then 5 mL of diluted HRP-conjugated glyceraldehyde-3-phosphate dehydrogenase antibody (diluted with TBST buffer containing 3% BSA, 1:8000 dilution) was added, incubated at room temperature for 1 hour, and Western blots were recorded with Invitrogen iBright 1500. The results are shown in Figure 2. Fig.10 As shown, the Kras protein content level in the blank control group was used as a standard to compare the delivery of GFP, RING-Mo in HeLa cells by metal organic frameworks. Ras The results of immunoblotting showed that the level of Kras did not change significantly when GFP was delivered alone (control group). Ras The delivery of Kras significantly reduced
[0108] RING-Mo Ras When the concentration of @MOF@Cet reached 40 μg / mL, the degradation rate of intracellular Kras was 49%.
[0109] Example 7: Delivery of fusion protein RING-Af via endolytic peptide L17E Syn Effect on the degradation of intracellular α-Synuclein
[0110] 1. Co-incubation of L17E and fusion protein
[0111] In three groups of EP tubes containing 500 μL of α-MEM medium, 0.76 μL, 1.5 μL, and 3 μL of the fusion protein RING-Af prepared by the method of Example 1 with an original concentration of 1 mg / mL were added respectively. Syn Pure protein solution (final concentrations were 90nM, 180nM, and 360nM, respectively), and then 20μL of the endogenous peptide L17E (final concentration was 40μM, the amino acid sequence is shown in SEQ ID NO.14) with an original concentration of 1mM was added to three groups of EP tubes, respectively, and named as Group 2, Group 3, and Group 4, and incubated at 25°C on a mixer for 30min in advance.
[0112] HeLa cells were seeded at 50,000 cells / well in a 24-well plate containing 500 μL of DMEM medium and incubated at 37°C with 5% CO.2 Cultured overnight in an incubator to allow cells to reach 80-90% confluence. Washed twice with serum-free minimum essential medium (α-MEM medium), culture wells were divided into 4 groups, 500 μL α-MEM medium was added to group 1, and the addition method of group 2, group 3, and group 4 was as shown above, and incubated at 25°C for 4 hours. The cells were washed twice with PBS, and 500 μL DMEM medium containing 10% FBS was added to each well, and incubated at 37°C, 5% CO 2 Incubate in incubator for 24 hours.
[0113] 2. Target protein immunoblotting
[0114] Each group was maintained at 37°C and 5% CO 2 After incubation in the incubator for 24 hours, the cells were washed twice with PBS, and then 50 μL of PBS containing 0.1% polyethylene glycol monooctylphenyl ether (Triton-X) and 1 μM phenylmethylsulfonyl fluoride (PMSF) was added, followed by 20 μL of 5×SDS loading buffer. After heating at 95°C for 10 minutes, the samples were separated by 15% SDS-PAGE and transferred to a membrane. The membrane was blocked with 3% skim milk powder in TBST buffer at room temperature for 1 hour, 5 mL of diluted α-Syn antibody (initial concentration 1 mg / mL, ab225866, Abcam, diluted with 3% BSA in TBST buffer, 1:2000 dilution) was added, and incubated overnight at 4°C. Then, 5 mL of diluted HRP-conjugated glyceraldehyde-3-phosphate dehydrogenase antibody (initial concentration 1 mg / mL, #HRP-60004, diluted with 3% BSA in TBST buffer, 1:8000 dilution) was added, and incubated at room temperature for 1 hour. Western blots were recorded with Invitrogen iBright 1500. The results are shown in Figure 2. Fig.11 As shown, the α-Syn protein content level of the blank control group was used as the standard. At the same L17E concentration, the α-Syn protein content level of the blank control group was compared with that of the RING-Af Syn After 16 h of incubation, immunoblotting results showed that RING-Af Syn As the concentration increases, the degradation rate of intracellular α-Syn increases, reaching 60%.
Claims
1. A fusion protein for targeted degradation of endogenous cellular proteins, characterized in that: The fusion protein is obtained by fusing the RING domain with E3 ubiquitin ligase activity at the N-terminus of the Trim21 protein with a binding molecule of an intracellular target protein through a connecting peptide; the binding molecule includes an affinity body, a nanobody or a pseudo-antibody that can bind to the target protein.
2. The fusion protein according to claim 1, characterized in that The amino acid sequence of the RING domain is shown in amino acids 8-94 in SEQ ID NO.
1.
3. The fusion protein according to claim 1, characterized in that The connecting peptide includes GGGGS or GGGGSGGGGS.
4. The fusion protein according to claim 1, characterized in that The target proteins include green fluorescent protein GFP, α-synuclein α-Synuclein, and Kirsten rat sarcoma viral oncogene homolog Kras.
5. The fusion protein according to claim 1, characterized in that The cells include human cervical cancer cells HeLa, human cervical cancer cells HeLa-GFP marked with green fluorescent protein, and human epidermal cancer cells A431.
6. The fusion protein according to claim 1, characterized in that The amino acid sequence of the fusion protein is one of the following: SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.
5.
7. Use of the fusion protein according to claim 1 in targeted degradation of endogenous target proteins in cells.
8. The use according to claim 7, characterized in that The application method is as follows: the fusion protein is delivered into the cell by means of a protein delivery medium, the fusion protein binds to the endogenous target protein of the cell, the RING in the fusion protein plays the role of E3 ubiquitin ligase, and the degradation of the endogenous target protein of the cell is achieved through the ubiquitin proteasome system; the protein delivery medium includes a metal organic framework MOF, an endolytic peptide L17E, and a transmembrane polypeptide A5K.
9. The use according to claim 8, characterized in that The method for delivering the fusion protein using the endosoluble peptide L17E or the transmembrane polypeptide A5K is as follows: the fusion protein is incubated with the endosoluble peptide L17E or the transmembrane polypeptide A5K at 25° C. for 30 minutes, and then incubated with cells, thereby delivering the fusion protein into the cells; the amino acid sequence of the endosoluble peptide L17E is shown in SEQ ID NO.14; the amino acid sequence of the transmembrane polypeptide A5K is shown in SEQ ID NO.
13.
10. The use according to claim 8, characterized in that The method for delivering the fusion protein using the metal organic framework MOF is as follows: (1) adding the pure protein solution of the fusion protein to an aqueous solution containing 2-methylimidazole under vigorous stirring at 30° C. and 1000 rpm, incubating for 5 minutes, then slowly dropping an aqueous solution of zinc nitrate hexahydrate, stirring at 30° C. and 1000 rpm for 10 minutes, centrifuging at 12000 rpm for 10 minutes, washing the precipitate with deionized water three times to remove the residue, and drying at 40° C. overnight to obtain a nano-metal organic framework loaded with the fusion protein; the protein concentration of the fusion protein aqueous solution is 2 mg / mL, and the concentration of the 2-methylimidazole aqueous solution is 3.5 M. The concentration of the zinc nitrate hexahydrate aqueous solution is 0.45M, the feed ratio of the fusion protein to 2-methylimidazole is 0.25mg / 3.15mmol, and the feed ratio of the fusion protein to zinc nitrate hexahydrate is 0.25mg / 0.045mmol; (2) diluting the nanometal organic framework loaded with the fusion protein in step (1) with deionized water, slowly adding the cetuximab Cet solution, and incubating at 4°C for 2 hours under continuous stirring to obtain a nanomaterial solution with antibody protein attached to the surface; (3) incubating the nanomaterial solution with antibody protein attached to the surface in step (2) with cells to deliver the fusion protein into the cells.
Citation Information
Cited By
Nucleic acid molecule targeting SARS-CoV-2 virus Spike protein, recombinant expression vector containing nucleic acid molecule and application
CN122146697A
